Montelukast Sun Pharma Italia Srl (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4 and E4 from binding. This inhibition reduces bronchoconstriction, vascular leakage and inflammatory cell recruitment in the airways, leading to improved breathing and reduced allergic symptoms.

The appropriate dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition and clinical response. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Montelukast is classified as pregnancy category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Limited data are available for breastfeeding; a decision should be made in consultation with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting β2‑agonists. It is particularly useful for patients who experience exercise‑induced bronchoconstriction or have allergic rhinitis, but it may be less potent than inhaled steroids for severe asthma control.

Montelukast tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include neuropsychiatric events such as mood changes, depression or suicidal thoughts, as well as rare allergic reactions like angioedema, Stevens‑Johnson syndrome and eosinophilic granulomatosis with polyangiitis. Any sudden or severe symptoms should prompt immediate medical attention.

Montelukast should be avoided in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it is not recommended for use in children under the approved age for the specific indication without physician guidance.